Newborn Mice Vaccination with BCG.HIVA222 plus MVA.HIVA Enhances HIV-1-Specific Immune Responses: Influence of Age and Immunization Routes

N Saubi, EJ Im, R Fernández-Lloris, O Gil, PJ Cardona, J Gatell, T Hanke, J Joseph

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

19 Cites (Scopus)

Resum

We have evaluated the influence of age and immunization routes for induction of HIV-1- and M. tuberculosis-specific immune responses after neonatal (7 days old) and adult (7 weeks old) BALB/c mice immunization with BCG.HIVA222 prime and MVA.HIVA boost. The specific HIV-1 cellular immune responses were analyzed in spleen cells. The body weight of the newborn mice was weekly recorded. The frequencies of HIV-specific CD8+ T cells producing IFN-γ were higher in adult mice vaccinated intradermally and lower in adult and newborn mice vaccinated subcutaneously. In all cases the IFN-γ production was significantly higher when mice were primed with BCG.HIVA222 compared with BCGwt. When the HIV-specific CTL activity was assessed, the frequencies of specific killing were higher in newborn mice than in adults. The prime-boost vaccination regimen which includes BCG.HIVA222 and MVA.HIVA was safe when inoculated to newborn mice. The administration of BCG.HIVA222 to newborn mice is safe and immunogenic and increased the HIV-specific responses induced by MVA.HIVA vaccine. It might be a good model for infant HIV and Tuberculosis bivalent vaccine.
Idioma originalAnglès
Número d’article516219
Nombre de pàgines11
RevistaClinical & developmental immunology
DOIs
Estat de la publicacióPublicada - 1 de gen. 2011

Fingerprint

Navegar pels temes de recerca de 'Newborn Mice Vaccination with BCG.HIVA222 plus MVA.HIVA Enhances HIV-1-Specific Immune Responses: Influence of Age and Immunization Routes'. Junts formen un fingerprint únic.

Com citar-ho